Robert Wiblin’s slide deck for his ‘good news’ talk at EAGx Australia (July 2022) has some good content.
From this talk, I’ll highlight:
Animal corporate campaigns really were working.
As of May 2022, 980, or 88%, of companies globally had fulfilled their commitment to stop buying caged eggs, which equates to over 100 million animals out of cages.
There had been a concern that companies wouldn’t follow through on their commitments, and some have delayed here and there. But seems like there’s also a reasonable level of success
Giving What We Can is accelerating again—I just checked now and they’re on over 8,060 full pledges, versus 6,621 at the start of 2022. With $3 billion pledged, it’s becoming its own quirky sort of megadonor.
Alvea: full speed ahead on vaccine innovation. It was running pre-clinical trials in mice and sheep within 60 days of its founding in 2021, and aims to produce a platform for developing vaccines cheaply and scalably so that they can reach developing countries faster.
Open Philanthropy launched programs in two new cause areas (the first in five years): South Asian Air Quality, and Global Aid Policy
Robert Wiblin’s slide deck for his ‘good news’ talk at EAGx Australia (July 2022) has some good content.
From this talk, I’ll highlight:
Animal corporate campaigns really were working.
As of May 2022, 980, or 88%, of companies globally had fulfilled their commitment to stop buying caged eggs, which equates to over 100 million animals out of cages.
There had been a concern that companies wouldn’t follow through on their commitments, and some have delayed here and there. But seems like there’s also a reasonable level of success
Giving What We Can is accelerating again—I just checked now and they’re on over 8,060 full pledges, versus 6,621 at the start of 2022. With $3 billion pledged, it’s becoming its own quirky sort of megadonor.
Alvea: full speed ahead on vaccine innovation. It was running pre-clinical trials in mice and sheep within 60 days of its founding in 2021, and aims to produce a platform for developing vaccines cheaply and scalably so that they can reach developing countries faster.
Open Philanthropy launched programs in two new cause areas (the first in five years): South Asian Air Quality, and Global Aid Policy